Elon Musk’s Neuralink has raised $650 million to continue advancing its brain implants for patients with paralysis and other disorders, the company said.
The series E funding round included such investors as ARK Invest, DFJ Growth, Founders Fund, G42, Human Capital, Lightspeed, QIA, Sequoia Capital, Thrive Capital, Valor Equity Partners, Vy Capital, according to a June 2 blog post.
Neuralink has secured FDA Breakthrough Device Designation for vision and speech restoration, and is currently conducting clinical trials at Phoenix-based Barrow Neurological Institute, The Miami Project to Cure Paralysis at the University of Miami, University Health Network (Toronto Western Hospital), and Cleveland Clinic Abu Dhabi.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.